FindTrial
Sign In

The significance of superior thyroid artery peak systolic velocity as an index for anti-thyroid drug withdrawal in Graves disease patients

The significance of superior thyroid artery peak systolic velocity as an index for anti-thyroid drug withdrawal in Graves disease patients

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ROC-17011585
Enrollment
Unknown
Registered
2017-06-07
Start date
2017-07-01
Completion date
Unknown
Last updated
2017-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Graves' disease

Interventions

normal STA-PSV group:no
high STA-PSV group:no

Sponsors

Affiliated nanhai hospital of southern medical university
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Graves disease patients in line with the criteria of anti-thyroid drug withdrawal, aged from 18 to 60 years old, after 12-18 months of standardized anti-thyroid drug treatment,thyroid narrowing, normal TSH and TRab.

Exclusion criteria

Exclusion criteria: Giant thyroid(> 80g), Graves disease relapse after surgery treatment (can not observe the superior thyroid artery), previous history of RAI treatment, hyperthyroidism eye disease, pregnant women.

Design outcomes

Primary

MeasureTime frame
TSH;superior thyroid artery peak systolic velocity;TRab;—

Countries

China

Contacts

Public ContactYihong TAN

Affiliated Nanhai Hospital of Southern Medical University

39972827@qq.com+86 18607575805

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026